Type 1,2, 3, 4a 4b 4c and type 5 are outdated now   Based on 2026 Fifth Universal Definition of Myocardial Infarction: Primary, Secondary & Procedure-Related MI Explained For years, every cardiology learner memorized MI as type 1, type 2, type 3, type 4a/4b/4c and type 5. In 2026, that numerical framework was replaced by a simpler clinical classification. The Fifth Universal Definition of Myocardial Infarction now groups MI into primary, secondary and procedure-related MI. The big change: Old numerical labels are replaced by three clinical categories: PRIMARY MI, SECONDARY MI and PROCEDURE-RELATED MI. Why did the definition change? The older type-based system was scientifically useful but became difficult to apply consistently, particularly when ischemia occurred during another acute illness, when the coronary mechanism was not atherothrombosis, or after PCI or cardiac surgery. The 2026 ESC/ACC/AHA/WHF document shifts the emphasis from memorizing numbers to identifying the clinical mechanism. The new three-part MI classification 1. Primary myocardial infarction Primary MI is a spontaneous MI caused by a primary acute coronary pathology. Importantly, it is broader than the old type 1 atherothrombotic concept. It can include acute coronary atherothrombosis as well as spontaneous coronary artery dissection, coronary embolism, coronary vasospasm and certain late stent/graft failures that behave as new coronary disease rather than immediate procedural complications. Think: the coronary artery itself has developed an acute primary problem. 2. Secondary myocardial infarction Secondary MI occurs when another acute condition creates a myocardial oxygen supply-demand imbalance and objective evidence supports infarction. Examples may include profound anemia, severe hypoxemia, shock, sustained tachyarrhythmia or marked hypertension in the appropriate clinical context. The distinction from myocardial injury remains crucial. Troponin elevation alone does not equal MI. There must be evidence that acute myocardial ischemia is responsible for the injury. Think: the heart is suffering because another acute illness has upset oxygen supply versus demand. 3. Procedure-related myocardial infarction Procedure-related MI is an infarction occurring as a complication of a percutaneous or surgical cardiac procedure. The new framework aims to use clinically meaningful, objective criteria rather than maintaining multiple numerical subtypes. The document distinguishes genuine procedure-related MI from isolated biomarker release after a procedure. Think: the infarction is directly linked to a cardiac procedure and has evidence of a coronary complication plus new myocardial damage. So what happened to old Type 3 MI? The term “type 3 MI” has been removed. When sudden cardiac death is believed to be due to MI but biomarker testing is unavailable, the event should be classified using the new clinical framework — primary, secondary or procedure-related — based on the setting and available clinical or post-mortem evidence. What about troponin? Troponin remains central, but the 2026 document sharpens the distinction between myocardial injury and myocardial infarction. Myocardial injury is defined by cardiac troponin above the 99th percentile upper reference limit. Acute injury requires a dynamic rise and/or fall. To diagnose MI, the troponin pattern must be accompanied by evidence of acute myocardial ischemia. High-yield rule: Troponin elevation = myocardial injury. Troponin elevation + evidence of acute ischemia = myocardial infarction. Sex-specific troponin thresholds receive more emphasis The Fifth Universal Definition supports sex-specific 99th percentile upper reference limits for cardiac troponin where validated assays provide them. The rationale is to reduce systematic under-recognition of myocardial injury and MI in women when a single universal threshold is used. MINOCA has also changed The document updates the terminology around MINOCA to “myocardial injury with non-obstructive coronary arteries,” emphasizing that a non-obstructive angiogram is a starting point for investigation rather than a final mechanism. Further testing may identify infarction, myocarditis, Takotsubo syndrome or another cause of injury. Old versus new: rapid revision table Older framework 2026 framework Core idea Type 1 MI Primary MI Spontaneous acute coronary pathology Type 2 MI Secondary MI Supply-demand imbalance due to another acute condition Type 3 MI Removed as a separate label Classify by clinical setting if MI likely caused death Type 4 / 5 MI Procedure-related MI Complication of PCI or cardiac surgery with objective evidence What changes for exam preparation? Do not rely only on the old numerical labels if a question explicitly asks about the 2026 Fifth Universal Definition. Primary MI is broader than old type 1 MI; it includes acute coronary mechanisms beyond atherothrombosis. Secondary MI is supply-demand imbalance caused by another acute condition. Procedure-related MI replaces the old type 4/5 structure for contemporary classification. Type 3 MI is no longer a separate category. Always distinguish myocardial injury from infarction: ischemia is the deciding concept. Frequently Asked Questions Are Type 1, 2, 3, 4 and 5 MI completely “wrong” now? They belong to the older Fourth Universal Definition framework. The 2026 Fifth Universal Definition replaces the numerical clinical classification with primary, secondary and procedure-related MI. Does every elevated troponin mean MI? No. Elevated troponin means myocardial injury. MI requires acute myocardial injury plus evidence of acute ischemia. What replaces Type 2 MI? Secondary myocardial infarction. What replaces Type 4 and Type 5 MI? Procedure-related myocardial infarction. What is the easiest memory trick? Primary = coronary problem. Secondary = another acute illness creates supply-demand imbalance. Procedure-related = complication of PCI or cardiac surgery.   Authoritative Sources American Heart Association — Fifth Universal Definition of Myocardial Infarction (2026) European Heart Journal — Fifth Universal Definition of Myocardial Infarction (2026) American College of Cardiology — summary of the 2026 Universal Definition   Medical disclaimer: This article is for medical education and does not replace individualized diagnosis or treatment decisions.

A drug that entered the CLL story as a rescue option after prior BTK therapy has now crossed a major line: pirtobrutinib is now FDA-approved for previously untreated CLL/SLL in adults without a known 17p deletion. The October 2, 2026 approval is based on the phase 3 BRUIN CLL-313 trial and makes the non-covalent BTK inhibitor relevant at the very start of the treatment pathway. Bottom line: Pirtobrutinib is no longer only a later-line CLL drug. In the newly approved population, it can be used as first-line therapy, and the phase 3 trial showed a marked progression-free survival advantage over bendamustine plus rituximab.   What exactly did the FDA approve? On October 2, 2026, the U.S. FDA approved pirtobrutinib (Jaypirca) for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known deletion of chromosome 17p. The approval was supported by BRUIN CLL-313, a randomized open-label phase 3 study. This wording matters. The approval is not a blanket “all untreated CLL” label. The pivotal trial excluded patients with known del(17p), a biologically high-risk group in which treatment selection remains especially dependent on molecular risk and contemporary guideline pathways. BRUIN CLL-313: the result students and clinicians should remember Population: 282 adults with previously untreated CLL/SLL and no known del(17p). Intervention: pirtobrutinib given until disease progression or unacceptable toxicity. Comparator: bendamustine plus rituximab for six cycles. Primary efficacy endpoint: progression-free survival assessed by independent review. At an estimated median PFS follow-up of 28 months, median PFS was not estimable in the pirtobrutinib arm versus 33.5 months with bendamustine-rituximab. Hazard ratio for progression or death: 0.20 (95% CI 0.11–0.37; p<0.0001) in the FDA summary. Exam memory line: BRUIN CLL-313 = untreated CLL/SLL, no known del(17p), pirtobrutinib versus bendamustine-rituximab, major PFS benefit. Why is pirtobrutinib different from older BTK inhibitors? Ibrutinib, acalabrutinib and zanubrutinib are covalent BTK inhibitors. They bind irreversibly to BTK at cysteine 481. Pirtobrutinib is a highly selective, reversible non-covalent BTK inhibitor. It can inhibit BTK without depending on that covalent C481 bond, which is one reason it became important in patients whose disease had progressed after a covalent BTK inhibitor. The biological concept is high yield: resistance to covalent BTK inhibition can emerge through changes in BTK itself or in downstream signaling. A non-covalent inhibitor uses a different binding strategy and can retain activity in some settings in which a prior covalent inhibitor has failed. Does this mean chemotherapy is finished in CLL? The direction of travel is clear: modern CLL management is increasingly built around targeted therapy rather than traditional chemoimmunotherapy. However, “chemotherapy is dead” is too absolute. Treatment still depends on age, comorbidity, disease genetics, prior therapy, drug availability, patient preference, duration of therapy and regional guidelines. What the new approval does show is how rapidly CLL is moving toward pathway-directed therapy. A non-covalent BTK inhibitor has now beaten a classic bendamustine-rituximab regimen in a first-line randomized study in the approved population. What should be checked before treatment? Confirm the diagnosis and indication for starting therapy; asymptomatic early CLL is often observed rather than treated immediately. Risk-stratify with FISH/cytogenetics and TP53 assessment, particularly because del(17p)/TP53-aberrant disease changes the treatment conversation. Review previous cardiovascular history, bleeding risk, infection history, concomitant medicines and drug interactions. Discuss continuous versus time-limited approaches and patient preferences where alternatives exist. Important adverse effects and practical cautions As with other agents in the BTK pathway, clinicians should remain alert to infection, cytopenias, bleeding, rhythm disturbances and other treatment-emergent toxicities described in the prescribing information. The exact risk profile is not identical across BTK inhibitors, and treatment choice should not be made by mechanism alone. Do not overgeneralize: A new indication does not mean pirtobrutinib is automatically the best first-line choice for every patient with CLL. Molecular risk, co-morbidity, competing regimens, guideline updates and access still matter. Why this update matters for NEET PG / INI-CET / FMGE learners Know the class: pirtobrutinib = non-covalent (reversible) BTK inhibitor. Know the disease: CLL/SLL. Know the 2026 first-line update: previously untreated adults without known del(17p). Know the trial: BRUIN CLL-313. Do not confuse pirtobrutinib with covalent BTK inhibitors such as ibrutinib, acalabrutinib and zanubrutinib. Frequently Asked Questions Is pirtobrutinib a first-line CLL drug now? Yes. In October 2026 the FDA approved it for adults with previously untreated CLL/SLL without a known 17p deletion. Is pirtobrutinib a covalent BTK inhibitor? No. It is a reversible, non-covalent BTK inhibitor. What trial supported the first-line approval? BRUIN CLL-313, which compared pirtobrutinib with bendamustine plus rituximab in previously untreated CLL/SLL without known del(17p). Does this approval include known del(17p) disease? The newly approved first-line population specified no known 17p deletion. High-risk del(17p)/TP53-aberrant disease should be managed according to dedicated contemporary pathways. Can asymptomatic CLL be treated just because a new drug is available? No. Treatment is started for accepted clinical indications; many patients with early asymptomatic CLL remain under active surveillance.   Authoritative Sources S. FDA — Pirtobrutinib approval for previously untreated CLL/SLL (Oct 2, 2026) gov — BRUIN CLL-313 (NCT05023980) Medical disclaimer: This article is for medical education and does not replace individualized diagnosis or treatment decisions.

For years, there was an easy examination question: “What is the major disadvantage of PCSK9 inhibitors?” One obvious answer was: they are injectable. Not anymore. On July 17, 2026, the US FDA approved enlicitide, marketed as Lipfendra, making it the first FDA-approved oral PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). In the pivotal clinical program, oral enlicitide produced roughly 56–59% placebo-adjusted reductions in LDL cholesterol at 24 weeks. For a once-daily tablet, that number deserves attention. HIGH-YIELD ONE-LINER: Enlicitide = first oral PCSK9 inhibitor that lowers LDL-C by 65%. WOW!   First, revise PCSK9 in 30 seconds The liver removes circulating LDL cholesterol using LDL receptors. After an LDL particle binds its receptor, the complex is internalized into the hepatocyte. Normally, the LDL receptor can be recycled back to the hepatocyte surface and used again. PCSK9 binds LDL receptors and promotes their degradation. ↑ PCSK9 → ↓ LDL receptors → ↑ circulating LDL-C Block PCSK9 → ↑ recycled LDL receptors → ↑ LDL clearance → ↓ LDL-C That is why PCSK9 became such an attractive therapeutic target. But didn’t we already have PCSK9 drugs? Yes. Alirocumab and evolocumab are monoclonal antibodies targeting PCSK9 and are administered subcutaneously. Inclisiran approaches the pathway differently: it uses small-interfering RNA to reduce hepatic PCSK9 synthesis and is also injectable. The conceptual change with enlicitide is simple: PCSK9 lowering has entered the tablet era. How effective is enlicitide? The FDA approval was supported by randomized, double-blind, placebo-controlled studies in adults with hypercholesterolemia receiving background lipid-lowering therapy. The primary efficacy measure was percentage change in LDL-C at week 24. Population Approx. baseline LDL-C Placebo-adjusted LDL-C reduction at week 24 ASCVD/high cardiovascular risk 96 mg/dL ~56% Heterozygous familial hypercholesterolemia 119 mg/dL ~59% These are substantial LDL reductions and explain why an oral PCSK9 inhibitor has generated considerable clinical interest. The CORALreef story In the Phase 3 CORALreef Lipids study, nearly all participants were receiving statins. At week 24, LDL-C fell markedly with enlicitide while remaining essentially unchanged in the placebo group. Enlicitide also reduced non-HDL cholesterol, apolipoprotein B and lipoprotein(a). The key teaching point is that enlicitide was not developed simply as a replacement for statins in untreated patients. It is a potent additional LDL-lowering option for patients who remain above their recommended LDL level despite background therapy. How does it compare with other oral non-statin drugs? The CORALreef AddOn study provided a useful short-term comparison in statin-treated patients whose LDL remained above target. At day 56, the reported mean LDL-C reductions were approximately: Treatment Approx. LDL-C reduction Enlicitide 65% Ezetimibe 28% Bempedoic acid 6% Bempedoic acid + ezetimibe 37% These are lipid-efficacy comparisons over a relatively short period, not comparisons of cardiovascular outcomes. They nevertheless illustrate the potency of oral PCSK9 inhibition. Does enlicitide replace statins? No. Statins remain foundational therapy for LDL lowering and cardiovascular risk reduction in appropriate patients. The more useful clinical question is what to add when statin therapy does not lower LDL sufficiently, or when treatment needs to be individualized because of tolerance, risk, access or other clinical considerations. Depending on the patient, non-statin options may include ezetimibe, bempedoic acid and PCSK9-directed therapies. Why 2026 is a big year for LDL management The 2026 ACC/AHA dyslipidemia guideline also updated the way clinicians think about lipid management, including explicit LDL-C goals and use of PREVENT-ASCVD equations for primary-prevention risk assessment. Borderline/intermediate-risk primary prevention: LDL-C <100 mg/dL High-risk primary prevention: LDL-C <70 mg/dL Very-high-risk ASCVD: LDL-C <55 mg/dL Very-high-risk ASCVD → think LDL-C <55 mg/dL. The guideline also emphasizes measuring lipoprotein(a), or Lp(a), at least once in adulthood. Together, the new guideline and the arrival of an oral PCSK9 inhibitor make lipid management one of the most important cardiovascular update areas of 2026. Is enlicitide safe? Across the major studies, overall adverse-event rates were broadly comparable between enlicitide and placebo. Reported adverse reactions included symptoms such as diarrhea and dizziness in relevant study populations. As with any newly introduced therapy, prescribing should follow the approved product information and the patient’s individual clinical context. A new drug should not be prescribed merely because an LDL value is elevated. Absolute cardiovascular risk, LDL level, prior therapy, tolerability, comorbidities and current guideline recommendations remain central. The limitation every doctor should understand Enlicitide has demonstrated powerful LDL lowering. But lowering LDL in a lipid-efficacy trial and directly demonstrating fewer myocardial infarctions, strokes or cardiovascular deaths are not identical endpoints. The pivotal studies established strong lipid effects. Long-term cardiovascular outcome evidence will be important in defining the drug’s ultimate place in preventive cardiology. The scientifically correct message today is: enlicitide markedly lowers LDL; the magnitude of its eventual cardiovascular-outcome benefit should be judged from dedicated outcome evidence. NEET-PG / INI-CET / FMGE Exam Box A patient with hypercholesterolemia is prescribed the first FDA-approved oral inhibitor of PCSK9. Which drug has been prescribed? Inclisiran Evolocumab Enlicitide Alirocumab Answer: C. Enlicitide Make these associations automatic: Enlicitide → oral PCSK9 inhibitor Evolocumab / Alirocumab → monoclonal antibodies against PCSK9 Inclisiran → siRNA → decreases hepatic PCSK9 synthesis The bigger story This is not simply another cholesterol tablet. For years, PCSK9-directed treatment meant an injection. Enlicitide changes that practical assumption. Whether oral administration substantially expands PCSK9 use will depend on cardiovascular outcome evidence, long-term safety, cost, availability and real-world adherence. But one fact has already changed: PCSK9 inhibition is no longer an injection-only strategy. And that is precisely the kind of update that separates current clinical medicine from an outdated textbook. Keep Hammering. Frequently Asked Questions What is the first oral PCSK9 inhibitor? Enlicitide (Lipfendra) is the first FDA-approved oral PCSK9 inhibitor. It was approved in July 2026 for adults with hypercholesterolemia, including HeFH. How much does enlicitide lower LDL cholesterol? Pivotal studies reported placebo-adjusted LDL-C reductions of roughly 56% at week 24 in an ASCVD/high-risk population and roughly 59% in patients with HeFH. Is enlicitide an injection? No. Enlicitide is an oral once-daily therapy, distinguishing it from previously approved injectable PCSK9-directed treatments. […]